BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 31361848)

  • 1. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
    Chan BM; Hochster HS; Lenz HJ
    Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
    Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
    Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2017 Jun; 16(2):85-92. PubMed ID: 28242161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
    Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
    Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
    [No Abstract]   [Full Text] [Related]  

  • 6. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
    Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.
    Xu J; Kim TW; Shen L; Sriuranpong V; Pan H; Xu R; Guo W; Han SW; Liu T; Park YS; Shi C; Bai Y; Bi F; Ahn JB; Qin S; Li Q; Wu C; Ma D; Lin D; Li J
    J Clin Oncol; 2018 Feb; 36(4):350-358. PubMed ID: 29215955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trifluridine/tipiracil for the treatment of metastatic gastric cancer.
    Kawazoe A; Shitara K
    Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):65-70. PubMed ID: 31920125
    [No Abstract]   [Full Text] [Related]  

  • 9. Integrated safety summary for trifluridine/tipiracil (TAS-102).
    Falcone A; Ohtsu A; Van Cutsem E; Mayer RJ; Buscaglia M; Bendell JC; Kopetz S; Bebeau P; Yoshino T
    Anticancer Drugs; 2018 Jan; 29(1):89-96. PubMed ID: 29176395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
    Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S
    BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
    Miyamoto Y; Lenz HJ; Baba H
    Expert Rev Clin Pharmacol; 2016; 9(3):355-65. PubMed ID: 26677869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer.
    Burness CB; Duggan ST
    Drugs; 2016 Sep; 76(14):1393-402. PubMed ID: 27568360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
    Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R
    Clin Transl Oncol; 2017 Feb; 19(2):227-235. PubMed ID: 27443414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
    Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
    Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T
    Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer.
    Sommerhäuser G; Kurreck A; Stintzing S; Heinemann V; von Weikersthal LF; Dechow T; Kaiser F; Karthaus M; Schwaner I; Fuchs M; König A; Roderburg C; Hoyer I; Quante M; Kiani A; Fruehauf S; Müller L; Reinacher-Schick A; Ettrich TJ; Stahler A; Modest DP
    BMC Cancer; 2022 Jul; 22(1):820. PubMed ID: 35897060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer.
    Martinez-Perez J; Riesco-Martinez MC; Garcia-Carbonero R
    Expert Opin Drug Saf; 2018 Jun; 17(6):643-650. PubMed ID: 29745737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAS-102: a novel antimetabolite for the 21st century.
    Uboha N; Hochster HS
    Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAS-102 for the treatment of metastatic colorectal cancer.
    Salvatore L; Rossini D; Moretto R; Cremolini C; Schirripa M; Antoniotti C; Marmorino F; Loupakis F; Falcone A; Masi G
    Expert Rev Anticancer Ther; 2015; 15(11):1283-92. PubMed ID: 26509228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
    Kuboki Y; Nishina T; Shinozaki E; Yamazaki K; Shitara K; Okamoto W; Kajiwara T; Matsumoto T; Tsushima T; Mochizuki N; Nomura S; Doi T; Sato A; Ohtsu A; Yoshino T
    Lancet Oncol; 2017 Sep; 18(9):1172-1181. PubMed ID: 28760399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.